XTL's lead drug candidate, rHuEPO for the treatment of multiple myeloma blood cancer, has been granted an orphan drug designation from the FDA. rHuEPO, has previously been approved for marketing by the FDA for other indications, and has for many years had annual sales of billions of dollars across the world for the treatment of severe anemia.
XTL is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC: XTLBY).
For more information, please contact XTL Investor Relations at Tel: +972-9-955-7080 or email: email@example.com.
SOURCE XTL Biopharmaceuticals Ltd